Abnormal Amyloid Beta Peptide Csf Concentration C5676623
An abnormal level of amyloid beta peptides in spinal fluid that may relate to brain health. Additional testing and clinical correlation are usually recommended.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizure activity
Unexpected convulsive episodes or staring spells associated with neuronal dysfunction.
This is a medical emergency. Seek immediate emergency care if a seizure occurs.
Sudden neurological deficit
Acute onset of weakness, numbness, speech loss, or vision changes indicating possible stroke.
Call emergency services immediately. This requires emergent evaluation for stroke.
Memory loss
(neurologic)Gradual onset of short-term memory difficulties, especially forgetting recent conversations or events.
Frequency: 80-90% of patients
Cognitive decline
(neurologic)Progressive difficulty with thinking, reasoning, and problem-solving tasks.
Frequency: 75-85% of patients
Word-finding difficulty
(neurologic)Struggling to recall words or names during conversation, often substituting unfamiliar terms.
Frequency: 60-70% of patients
Disorientation to time
(neurologic)Confusion about the current date, day of week, or season.
Frequency: 55-65% of patients
Difficulty with familiar tasks
(neurologic)Trouble completing routine activities like cooking, managing finances, or driving.
Frequency: 50-60% of patients
Sleep disturbance
(neurologic)Changes in sleep patterns, including insomnia, frequent nighttime waking, or daytime drowsiness.
Frequency: 45-55% of patients
Gait disturbance
(neurologic)Unsteady walking, shuffling gait, or balance problems increasing fall risk.
Frequency: 20-30% of patients
Personality changes
(psychiatric)Noticeable shifts in mood, temperament, or social behavior, including apathy or irritability.
Frequency: 25-35% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Comprehensive CSF Panel Testing
Full analysis of amyloid beta peptide ratios and concentrations in cerebrospinal fluid to establish baseline and monitor changes.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Aerobic Exercise Program
Regular cardiovascular exercise such as walking, swimming, or cycling to support cerebral blood flow and potentially influence amyloid metabolism.
Additional treatment options
Brain-Healthy Nutrition Plan
Dietary approach focusing on antioxidant-rich foods, omega-3 fatty acids, and limited processed sugars to support overall neurological wellness.
dietaryCholinesterase Inhibitor Evaluation
Assessment for potential benefit of medications that may support cognitive function in patients with abnormal amyloid profiles.
medicationOmega-3 Fatty Acid Supplementation
Fish oil supplementation containing EPA and DHA to potentially support neuronal membrane health and inflammatory responses.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Amyloid Beta Peptide Csf Concentration C5676623?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234.
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684.
Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects. EMBO Mol Med. 2018;10(12):e9488.
Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(Pt 11):2837-2844.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
Hampel H, Wilcock G, Zetterberg H, et al. Biological markers for approaches to select, monitor, and treat subjects at risk for Alzheimer's disease. J Intern Med. 2011;269(4):367-381.
van Harten AC, Smits LL, Teunissen CE, et al. Preclinical AD predictions: a comparison of different biomarkers. Neurology. 2011;76(24):e108.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
Medication Comparisons
Compare medications used to treat Abnormal Amyloid Beta Peptide Csf Concentration C5676623. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy